ProteoBridge Inc. Raises 40 Million JPY in Third-Party Allocation with JMTC Capital LLC

ProteoBridge Inc. has raised 40 million JPY through a third-party allocation of shares, with JMTC Capital LLC (Head Office: Chuo-ku, Tokyo; CEO: Koyu Urata) as the allottee.

The funds will be used to enhance the quality of our A-Cube® Autoantibody Testing Service and HuPEX® Comprehensive Protein Array Contract Analysis Service, as well as to accelerate the development of new products, with the goal of increasing our corporate value.

JMTC Capital LLC: https://www.jmtc.co.jp/en/